GH Research Plc (GHRS)
19.10
+0.61
(+3.30%)
USD |
NASDAQ |
Nov 13, 16:00
18.73
-0.37
(-1.94%)
Pre-Market: 19:59
GH Research Enterprise Value : 948.78M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 948.78M |
| November 12, 2026 | 906.91M |
| November 11, 2026 | 959.07M |
| November 10, 2026 | 980.35M |
| November 09, 2026 | 959.76M |
| November 06, 2026 | 915.14M |
| November 05, 2026 | 903.47M |
| November 04, 2026 | 1.006B |
| November 03, 2026 | 1.030B |
| November 02, 2026 | 1.045B |
| October 30, 2026 | 1.070B |
| October 29, 2026 | 1.114B |
| October 28, 2026 | 1.059B |
| October 27, 2026 | 1.012B |
| October 26, 2026 | 954.27M |
| October 23, 2026 | 878.08M |
| October 22, 2026 | 907.59M |
| October 21, 2026 | 935.74M |
| October 20, 2026 | 953.24M |
| October 19, 2026 | 892.49M |
| October 16, 2026 | 883.57M |
| October 15, 2026 | 928.87M |
| October 14, 2026 | 911.71M |
| October 13, 2026 | 931.62M |
| October 12, 2026 | 1.012B |
| Date | Value |
|---|---|
| October 09, 2026 | 1.087B |
| October 08, 2026 | 1.041B |
| October 07, 2026 | 1.083B |
| October 06, 2026 | 1.115B |
| October 05, 2026 | 1.160B |
| October 02, 2026 | 1.212B |
| October 01, 2026 | 1.207B |
| September 30, 2026 | 1.249B |
| September 29, 2026 | 1.331B |
| September 28, 2026 | 1.245B |
| September 25, 2026 | 1.274B |
| September 24, 2026 | 1.316B |
| September 23, 2026 | 1.420B |
| September 22, 2026 | 1.550B |
| September 21, 2026 | 1.555B |
| September 18, 2026 | 1.578B |
| September 17, 2026 | 1.609B |
| September 16, 2026 | 1.543B |
| September 15, 2026 | 1.529B |
| September 14, 2026 | 1.552B |
| September 11, 2026 | 1.505B |
| September 10, 2026 | 1.510B |
| September 09, 2026 | 1.529B |
| September 08, 2026 | 1.545B |
| September 04, 2026 | 1.575B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Avadel Pharmaceuticals Plc | -- |
| Jazz Pharmaceuticals Plc | 18.27B |
| Cosmo NV | -- |
| AstraZeneca PLC | 598.40B |
| GSK Plc | 128.16B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.15M |
| Total Expenses (Quarterly) | 15.15M |
| EPS Diluted (Quarterly) | -0.2276 |
| Earnings Yield | -5.17% |
| Normalized Earnings Yield | -5.650 |